Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 76
Selected: 0
NCT IDTitle
NCT03644303Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.
NCT04116775Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.
NCT02300324The Bioavailability Of Sulforaphane From Broccoli Soups Study (BOBS)
NCT04457232Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation
NCT05702619Hypoxia-driven Prostate Cancer Genomics (HYPROGEN)
NCT01961713Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy
NCT04447703Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study
NCT00744549Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance
NCT05078151Whole-Body Diffusion-Weighted Magnetic Resonance Imaging (MRI) as a Response Biomarker for Metastatic Prostate Cancer
NCT00953576Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer
NCT06046040TmPSMA-02 in mCRPC
NCT04090528pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
NCT02445976Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.
NCT03276572Phase I Trial of 225Ac-J591 in Patients With mCRPC
NCT03358563Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer
NCT01703065Cabozantinib in Men With Castration-Resistant Prostate Cancer
NCT01417182Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer
NCT00156884A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer
NCT02856100Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer
NCT02582697Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
NCT05445609Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
NCT04824937Telaglenastat + Talazoparib In Prostate Cancer
NCT04430192Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy
NCT02135484Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases
NCT03532217Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
NCT03477864Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer
NCT02985021Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
NCT05113537Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
NCT05320406RElugolix VErsus LeUprolide Cardiac Trial
NCT05327465Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy
NCT0471672568Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
NCT05435495Mechanisms of Resistance to PSMA Radioligand Therapy
NCT02735252PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer
NCT02677376Imaging Biomarkers to Validate Response in Enzalutamide-Treated mCRPC
NCT03031821Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome
NCT03007732Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
NCT05150236EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC
NCT04343885In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy
NCT03761160Mobile Health App to Mitigate the Metabolic Effects of Androgen Deprivation Therapy
NCT06305598Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
NCT06126731Combination Study of Antibiotics With Enzalutamide (PROMIZE)
NCT01950143Effect of Sulforaphane on Prostate CAncer PrEvention
NCT06714630The PROSECCA Study, Answering New Questions in Prostate Cancer
NCT06449664Training for Men Undergoing Androgen Deprivation Therapy.
NCT00651222Influence of Hormone Therapy on Heart Attack Incidence in Men Undergoing Prostate Brachytherapy
NCT03392428A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer
NCT07050433COMPASS Study for Metastatic Castration-resistant Prostate Cancer
NCT03440554Non-contrast MR Imaging for Whole Body Cancer Detection and Characterization
NCT06171139Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer
NCT06616597Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer